BC Week In Review | Aug 11, 2017
Clinical News

Avelas starts Phase II of imaging agent AVB-620 in patients with primary breast cancer

Avelas Biosciences Inc. (La Jolla, Calif.) began a Phase II trial to evaluate a single dose of IV AVB-620 administered prior to surgery to detect malignant tissue in about 100 women with primary, non-recurrent, non-metastatic...
BC Week In Review | Feb 3, 2017
Clinical News

AVB-620: Ph Ib data

Data from about 15 patients with primary, non-recurrent breast cancer undergoing surgery in an open-label, dose-escalation, U.S. Phase Ib trial showed that a single dose of IV AVB-620 administered prior to surgery led to no...
BC Extra | Aug 18, 2016
Financial News

Avelas' series C round brings in $20M

Avelas Biosciences Inc. (La Jolla, Calif.) raised $20 million in a series C financing led by the Pharmstandard International S.A. subsidiary of Pharmstandard OJSC (RTS:PHST; LSE:PHST). New investors Ervington Investments and Alexandria Venture Investments participated,...
BC Week In Review | Nov 16, 2015
Clinical News

AVB-620: Phase I started

Avelas began an open-label, dose-escalation, U.S. Phase I trial to evaluate single doses of IV AVB-620 in up to 39 patients with stage I-III breast cancer prior to surgery. Avelas Biosciences Inc. , La Jolla, Calif....
Items per page:
1 - 4 of 4